Literature DB >> 15089975

Oxytocin and oxytocin receptors in cancer cells and proliferation.

P Cassoni1, A Sapino, T Marrocco, B Chini, G Bussolati.   

Abstract

The hypothalamic nonapeptide oxytocin plays a crucial role in many reproductive and behavioural functions. However, in recent years, an additional new role for oxytocin has been identified in neoplastic pathology. In tumours, oxytocin acts as a growth regulator, through the activation of a specific G-coupled transmembrane receptor, the oxytocin receptor. In vitro, oxytocin inhibits proliferation of neoplastic cells of either epithelial (mammary and endometrial), nervous or bone origin, all expressing oxytocin receptor. Furthermore, an oxytocin growth-inhibiting effect was also tested and confirmed in vivo in mouse and rat mammary carcinomas. In neoplastic cells derived from two additional oxytocin target tissues, trophoblast and endothelium, oxytocin was found to promote cell proliferation, an effect opposite to that previously described in all other neoplastic oxytocin-responsive cells. The signal transduction pathways coupled to the biological effects of oxytocin are different in oxytocin growth-inhibited or growth-stimulated cells, and may depend on the membrane localization of the oxytocin receptor itself. The inhibitory effect of oxytocin is apparently mediated by activation of the cAMP-protein kinase A pathway, a nonconventional oxytocin signalling pathway, whereas the mitogenic effect is coupled to the increase of intracellular [Ca(2+)] and tyrosine phosphorylation, 'classical' oxytocin transducers. Moreover, the oxytocin receptor localization in lipid rafts enriched in caveolin-1 turns the inhibition of cell growth into a proliferative response, eliciting different epidermal growth factor receptor/mitogen-activated protein kinase activation patterns. This unexpected role of oxytocin (and oxytocin analogues) in regulating cell proliferation, as well as the widespread expression of oxytocin receptors in neoplastic tissues of different origin, opens up new perspectives on the biological role of the oxytocin-oxytocin receptor system in cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15089975     DOI: 10.1111/j.0953-8194.2004.01165.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  18 in total

1.  Oxytocin increases invasive properties of endometrial cancer cells through phosphatidylinositol 3-kinase/AKT-dependent up-regulation of cyclooxygenase-1, -2, and X-linked inhibitor of apoptosis protein.

Authors:  Marie-Claude Déry; Parvesh Chaudhry; Valérie Leblanc; Sophie Parent; Anne-Marie Fortier; Eric Asselin
Journal:  Biol Reprod       Date:  2011-08-03       Impact factor: 4.285

2.  Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jennifer C Carr; Scott K Sherman; Donghong Wang; Fadi S Dahdaleh; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2013-10-10       Impact factor: 5.344

3.  Hypothalamus-pituitary-thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system.

Authors:  María Pilar Carrera-González; María Jesús Ramírez-Expósito; Jose Manuel Arias de Saavedra; Rafael Sánchez-Agesta; María Dolores Mayas; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2011-01-05

4.  Oxytocin administration attenuates atherosclerosis and inflammation in Watanabe Heritable Hyperlipidemic rabbits.

Authors:  Angela Szeto; Maria A Rossetti; Armando J Mendez; Crystal M Noller; Edward E Herderick; Julie A Gonzales; Neil Schneiderman; Philip M McCabe
Journal:  Psychoneuroendocrinology       Date:  2012-09-19       Impact factor: 4.905

5.  Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer.

Authors:  Trisheena Harricharran; Olorunseun O Ogunwobi
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2019-12-14

6.  Stress buffering effects of oxytocin on HIV status in low-income ethnic minority women.

Authors:  Erin M Fekete; Michael H Antoni; Corina Lopez; Armando J Mendez; Angela Szeto; Mary Ann Fletcher; Nancy Klimas; Mahendra Kumar; Neil Schneiderman
Journal:  Psychoneuroendocrinology       Date:  2011-01-06       Impact factor: 4.905

7.  Effect of oxytocin on neuroblastoma cell viability and growth.

Authors:  Jan Bakos; Vladimir Strbak; Nina Ratulovska; Zuzana Bacova
Journal:  Cell Mol Neurobiol       Date:  2012-01-18       Impact factor: 5.046

Review 8.  Salubrious effects of oxytocin on social stress-induced deficits.

Authors:  Adam S Smith; Zuoxin Wang
Journal:  Horm Behav       Date:  2011-12-08       Impact factor: 3.587

9.  Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Authors:  Michaela G Cuneo; Angela Szeto; Andrew Schrepf; Ellen M Kinner; Benjamin I Schachner; Raisa Ahmed; Premal H Thaker; Michael Goodheart; David Bender; Steve W Cole; Philip M McCabe; Anil K Sood; Susan K Lutgendorf; Armando J Mendez
Journal:  Psychoneuroendocrinology       Date:  2019-04-06       Impact factor: 4.905

10.  Oxytocin does not attenuate the ex vivo production of inflammatory cytokines by lipopolysaccharide-activated monocytes and macrophages from healthy male and female donors.

Authors:  Kharah M Ross; Gaye McDonald-Jones; Gregory E Miller
Journal:  Neuroimmunomodulation       Date:  2013-07-27       Impact factor: 2.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.